GB201512203D0 - Agents,uses and methods - Google Patents

Agents,uses and methods

Info

Publication number
GB201512203D0
GB201512203D0 GBGB1512203.9A GB201512203A GB201512203D0 GB 201512203 D0 GB201512203 D0 GB 201512203D0 GB 201512203 A GB201512203 A GB 201512203A GB 201512203 D0 GB201512203 D0 GB 201512203D0
Authority
GB
United Kingdom
Prior art keywords
agents
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1512203.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to GBGB1512203.9A priority Critical patent/GB201512203D0/en
Publication of GB201512203D0 publication Critical patent/GB201512203D0/en
Priority to JOP/2016/0140A priority patent/JO3692B1/ar
Priority to ARP160102110A priority patent/AR105336A1/es
Priority to CN202210997939.4A priority patent/CN115925921A/zh
Priority to LTEPPCT/EP2016/066476T priority patent/LT3322722T/lt
Priority to GEAP202014670A priority patent/GEAP202014670A/en
Priority to CA2989735A priority patent/CA2989735C/en
Priority to FIEP16738736.4T priority patent/FI3322722T3/fi
Priority to TW105121902A priority patent/TWI729992B/zh
Priority to HRP20250624TT priority patent/HRP20250624T1/hr
Priority to PE2018000066A priority patent/PE20181049A1/es
Priority to CR20230300A priority patent/CR20230300A/es
Priority to JP2018501163A priority patent/JP7012004B2/ja
Priority to ES16738736T priority patent/ES3028882T3/es
Priority to PL16738736.4T priority patent/PL3322722T3/pl
Priority to UAA201800664A priority patent/UA125501C2/uk
Priority to PT167387364T priority patent/PT3322722T/pt
Priority to CN202511963296.1A priority patent/CN121736097A/zh
Priority to RS20250497A priority patent/RS66840B1/sr
Priority to RU2017145653A priority patent/RU2765303C2/ru
Priority to EP16738736.4A priority patent/EP3322722B1/en
Priority to GEAP201614670A priority patent/GEP20207151B/en
Priority to NZ738315A priority patent/NZ738315B2/en
Priority to DK16738736.4T priority patent/DK3322722T3/da
Priority to BR112017027506-6A priority patent/BR112017027506B1/pt
Priority to TNP/2018/000005A priority patent/TN2018000005A1/en
Priority to EP25154059.7A priority patent/EP4582144A3/en
Priority to MYPI2017001926A priority patent/MY194944A/en
Priority to MA42439A priority patent/MA42439B1/fr
Priority to HUE16738736A priority patent/HUE071541T2/hu
Priority to AU2016292896A priority patent/AU2016292896B2/en
Priority to SI201631902T priority patent/SI3322722T1/sl
Priority to PCT/EP2016/066476 priority patent/WO2017009312A1/en
Priority to CN202511963248.2A priority patent/CN121824750A/zh
Priority to KR1020257011170A priority patent/KR20250051158A/ko
Priority to CN201680039417.6A priority patent/CN107709361A/zh
Priority to US15/207,859 priority patent/US10800836B2/en
Priority to KR1020177037733A priority patent/KR102793383B1/ko
Priority to HK18113434.7A priority patent/HK1254358B/en
Priority to MX2018000504A priority patent/MX2018000504A/es
Priority to EA201792616A priority patent/EA036499B1/ru
Priority to CR20180021A priority patent/CR20180021A/es
Priority to US15/812,363 priority patent/US10364285B2/en
Priority to US15/812,303 priority patent/US10358483B2/en
Priority to US15/812,410 priority patent/US10358484B2/en
Priority to US15/812,251 priority patent/US10358482B2/en
Priority to CONC2017/0012941A priority patent/CO2017012941A2/es
Priority to ZA2017/08607A priority patent/ZA201708607B/en
Priority to IL256501A priority patent/IL256501B/en
Priority to PH12018500016A priority patent/PH12018500016A1/en
Priority to CL2018000075A priority patent/CL2018000075A1/es
Priority to DO2018000013A priority patent/DOP2018000013A/es
Priority to NI201800006A priority patent/NI201800006A/es
Priority to SV2018005612A priority patent/SV2018005612A/es
Priority to ECIEPI20182645A priority patent/ECSP18002645A/es
Priority to MX2023009483A priority patent/MX2023009483A/es
Priority to US16/443,225 priority patent/US10647764B2/en
Priority to US16/443,249 priority patent/US10640554B2/en
Priority to US16/443,187 priority patent/US10647763B2/en
Priority to US16/895,471 priority patent/US11524995B2/en
Priority to US17/004,447 priority patent/US11421024B2/en
Priority to US17/088,307 priority patent/US11542323B2/en
Priority to JP2021136539A priority patent/JP7138322B2/ja
Priority to JP2022136108A priority patent/JP7608404B2/ja
Priority to US17/992,403 priority patent/US20230312693A1/en
Priority to JP2024221962A priority patent/JP2025041734A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
GBGB1512203.9A 2015-07-13 2015-07-13 Agents,uses and methods Ceased GB201512203D0 (en)

Priority Applications (66)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
JOP/2016/0140A JO3692B1 (ar) 2015-07-13 2016-07-11 عوامل، استخدامات وطرق لعلاج مرض تنكسي عصبي
ARP160102110A AR105336A1 (es) 2015-07-13 2016-07-12 Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CN202210997939.4A CN115925921A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
LTEPPCT/EP2016/066476T LT3322722T (lt) 2015-07-13 2016-07-12 Agentai, jų panaudojimo būdai ir metodai, skirti sinukleopatijos gydymui
GEAP202014670A GEAP202014670A (en) 2015-07-13 2016-07-12 Agents, Uses and Methods for the Treatment of Synucleinopathy
CA2989735A CA2989735C (en) 2015-07-13 2016-07-12 Antibodies binding alpha-synuclein and uses thereof for the treatment of synucleinopathy
FIEP16738736.4T FI3322722T3 (fi) 2015-07-13 2016-07-12 Aineita, käyttötapoja ja menetelmiä synukleinopatian hoitoon
TW105121902A TWI729992B (zh) 2015-07-13 2016-07-12 用於治療共核蛋白病的藥劑、用途及方法
HRP20250624TT HRP20250624T1 (hr) 2015-07-13 2016-07-12 Sredstva, uporaba i metode za liječenje sinukleinopatije
PE2018000066A PE20181049A1 (es) 2015-07-13 2016-07-12 Agentes, usos y metodos para el tratamiento de la sinucleinopatia
CR20230300A CR20230300A (es) 2015-07-13 2016-07-12 ANTICUERPOS PARA EL TRATAMIENTO DE SINUCLEINOPATÍAS (Divisional expediente 2018-0021)
JP2018501163A JP7012004B2 (ja) 2015-07-13 2016-07-12 シヌクレイノパチーの治療のための薬剤、使用および方法
ES16738736T ES3028882T3 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
PL16738736.4T PL3322722T3 (pl) 2015-07-13 2016-07-12 Środki, zastosowania i sposoby leczenia synukleinopatii
UAA201800664A UA125501C2 (uk) 2015-07-13 2016-07-12 Моноклональне антитіло, або його антигензв'язувальний фрагмент, яке здатне специфічно зв'язуватися з альфа-синуклеїном людини, його застосування та спосіб лікування синуклеопатії
PT167387364T PT3322722T (pt) 2015-07-13 2016-07-12 Agentes, utilizações e métodos para o tratamento de sinucleinopatia
CN202511963296.1A CN121736097A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
RS20250497A RS66840B1 (sr) 2015-07-13 2016-07-12 Agensi, koristi i postupci za lečenje sinukleinopatije
RU2017145653A RU2765303C2 (ru) 2015-07-13 2016-07-12 Средства, пути применения и способы лечения синуклеопатии
EP16738736.4A EP3322722B1 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
GEAP201614670A GEP20207151B (en) 2015-07-13 2016-07-12 Agents, Uses and Methods for the Treatment of Synucleinopathy
NZ738315A NZ738315B2 (en) 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
DK16738736.4T DK3322722T3 (da) 2015-07-13 2016-07-12 Midler, anvendelser og fremgangsmåder til behandling af synukleinopati
BR112017027506-6A BR112017027506B1 (pt) 2015-07-13 2016-07-12 Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo, preparação, composição farmacêutica, uso dos mesmos e kit para o tratamento de sinucleinopatia
TNP/2018/000005A TN2018000005A1 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
EP25154059.7A EP4582144A3 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
MYPI2017001926A MY194944A (en) 2015-07-13 2016-07-12 Agents, Uses and Methods for the Treatment of Synucleinopathy
MA42439A MA42439B1 (fr) 2015-07-13 2016-07-12 Agents, utilisations et procédés pour le traitement d'une synucléinopathie
HUE16738736A HUE071541T2 (hu) 2015-07-13 2016-07-12 Anyagok, alkalmazások és eljárások szinukleinopátia kezelésére
AU2016292896A AU2016292896B2 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
SI201631902T SI3322722T1 (sl) 2015-07-13 2016-07-12 Sredstva, uporaba in metode za zdravljenje sinukleinopatije
PCT/EP2016/066476 WO2017009312A1 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
CN202511963248.2A CN121824750A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
KR1020257011170A KR20250051158A (ko) 2015-07-13 2016-07-12 시누클레인병증의 치료를 위한 제제, 용도 및 방법
CN201680039417.6A CN107709361A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
US15/207,859 US10800836B2 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
KR1020177037733A KR102793383B1 (ko) 2015-07-13 2016-07-12 시누클레인병증의 치료를 위한 제제, 용도 및 방법
HK18113434.7A HK1254358B (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy
MX2018000504A MX2018000504A (es) 2015-07-13 2016-07-12 Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
EA201792616A EA036499B1 (ru) 2015-07-13 2016-07-12 Моноклональное антитело, которое способно специфически связываться с альфа-синуклеином человека
CR20180021A CR20180021A (es) 2015-07-13 2016-07-12 Agentes, usos y métodos para el tratmiento de la sinucleinopatía
US15/812,363 US10364285B2 (en) 2015-07-13 2017-11-14 Antibodies for the treatment of synucleinopathy
US15/812,303 US10358483B2 (en) 2015-07-13 2017-11-14 Antibodies for the treatment of synucleinopathy
US15/812,410 US10358484B2 (en) 2015-07-13 2017-11-14 Antibodies for the treatment of synucleinopathy
US15/812,251 US10358482B2 (en) 2015-07-13 2017-11-14 Antibodies for the treatment of synucleinopathy
CONC2017/0012941A CO2017012941A2 (es) 2015-07-13 2017-12-15 Agentes, usos y métodos para el tratamiento de la sinucleinopatía
ZA2017/08607A ZA201708607B (en) 2015-07-13 2017-12-18 Agents, uses and methods for the treatment of synucleinopathy
IL256501A IL256501B (en) 2015-07-13 2017-12-22 Causes, uses and methods of treating synuclein pathology
PH12018500016A PH12018500016A1 (en) 2015-07-13 2018-01-03 Agents, uses and methods for the treatment of synucleinopathy
CL2018000075A CL2018000075A1 (es) 2015-07-13 2018-01-09 Agentes, usos y métodos para el tratamiento de la sinucleinopatía.
DO2018000013A DOP2018000013A (es) 2015-07-13 2018-01-11 Agentes, usos y métodos para el tratamiento de la sinucleinopatía
NI201800006A NI201800006A (es) 2015-07-13 2018-01-11 Agentes, usos y métodos para el tratamiento de la sinucleinopatía
SV2018005612A SV2018005612A (es) 2015-07-13 2018-01-11 Agentes, usos y metodos para el tratamiento de la sinucleinopatia
ECIEPI20182645A ECSP18002645A (es) 2015-07-13 2018-01-12 Agentes, usos y métodos para el tratamiento de la sinucleinopatía
MX2023009483A MX2023009483A (es) 2015-07-13 2018-01-12 Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
US16/443,225 US10647764B2 (en) 2015-07-13 2019-06-17 Agents, uses and methods for the treatment of synucleinopathy
US16/443,249 US10640554B2 (en) 2015-07-13 2019-06-17 Agents, uses and methods for the treatment of synucleinopathy
US16/443,187 US10647763B2 (en) 2015-07-13 2019-06-17 Agents, uses and methods for the treatment of synucleinopathy
US16/895,471 US11524995B2 (en) 2015-07-13 2020-06-08 Agents, uses and methods for the treatment of synucleinopathy
US17/004,447 US11421024B2 (en) 2015-07-13 2020-08-27 Agents, uses and methods for the treatment of synucleinopathy
US17/088,307 US11542323B2 (en) 2015-07-13 2020-11-03 Agents, uses and methods for the treatment of synucleinopathy
JP2021136539A JP7138322B2 (ja) 2015-07-13 2021-08-24 シヌクレイノパチーの治療のための薬剤、使用および方法
JP2022136108A JP7608404B2 (ja) 2015-07-13 2022-08-29 シヌクレイノパチーの治療のための薬剤、使用および方法
US17/992,403 US20230312693A1 (en) 2015-07-13 2022-11-22 Agents, Uses and Methods for the Treatment of Synucleinopathy
JP2024221962A JP2025041734A (ja) 2015-07-13 2024-12-18 シヌクレイノパチーの治療のための薬剤、使用および方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Publications (1)

Publication Number Publication Date
GB201512203D0 true GB201512203D0 (en) 2015-08-19

Family

ID=54013851

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1512203.9A Ceased GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods

Country Status (40)

Country Link
US (12) US10800836B2 (https=)
EP (2) EP4582144A3 (https=)
JP (4) JP7012004B2 (https=)
KR (2) KR102793383B1 (https=)
CN (4) CN121736097A (https=)
AR (1) AR105336A1 (https=)
AU (1) AU2016292896B2 (https=)
CL (1) CL2018000075A1 (https=)
CO (1) CO2017012941A2 (https=)
CR (2) CR20230300A (https=)
DK (1) DK3322722T3 (https=)
DO (1) DOP2018000013A (https=)
EA (1) EA036499B1 (https=)
EC (1) ECSP18002645A (https=)
ES (1) ES3028882T3 (https=)
FI (1) FI3322722T3 (https=)
GB (1) GB201512203D0 (https=)
GE (2) GEAP202014670A (https=)
HR (1) HRP20250624T1 (https=)
HU (1) HUE071541T2 (https=)
IL (1) IL256501B (https=)
JO (1) JO3692B1 (https=)
LT (1) LT3322722T (https=)
MA (1) MA42439B1 (https=)
MX (2) MX2018000504A (https=)
MY (1) MY194944A (https=)
NI (1) NI201800006A (https=)
PE (1) PE20181049A1 (https=)
PH (1) PH12018500016A1 (https=)
PL (1) PL3322722T3 (https=)
PT (1) PT3322722T (https=)
RS (1) RS66840B1 (https=)
RU (1) RU2765303C2 (https=)
SI (1) SI3322722T1 (https=)
SV (1) SV2018005612A (https=)
TN (1) TN2018000005A1 (https=)
TW (1) TWI729992B (https=)
UA (1) UA125501C2 (https=)
WO (1) WO2017009312A1 (https=)
ZA (1) ZA201708607B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937210A (zh) * 2016-11-15 2019-06-25 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
IL269550B2 (en) 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF
EP3725802A4 (en) * 2017-11-17 2021-08-11 ABL Bio Inc. Antibodies to alpha-synuclein and uses thereof
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
KR20200115590A (ko) * 2018-01-26 2020-10-07 퀀텀-에스아이 인코포레이티드 서열화 디바이스들을 위한 머신 학습 가능형 펄스 및 염기 호출
CA3091135A1 (en) * 2018-02-12 2019-08-15 The Scripps Research Institute Methods related to parkinson's disease and synucleinopathies
WO2020033756A1 (en) * 2018-08-09 2020-02-13 F. Hoffmann-La Roche Ag Determination of parkinson's disease
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
KR20210154179A (ko) * 2019-04-18 2021-12-20 에이씨 이뮨 에스.에이. 치료 및 진단용 신규한 분자
US20220226357A1 (en) * 2019-04-29 2022-07-21 Thomas Jefferson University Methods for treating neurodegenerative disorders
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
EP4395894A4 (en) * 2021-09-01 2025-08-06 Vaxxinity Inc METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES
KR20240055758A (ko) 2021-09-16 2024-04-29 하. 룬드벡 아크티에셀스카브 시누클레인병증을 치료하기 위한 조성물 및 방법
CN117430686B (zh) * 2022-07-22 2025-07-01 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
WO2024177999A2 (en) * 2023-02-21 2024-08-29 The Regents Of The University Of Michigan Human aggregated alpha-synuclein binding molecules
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途
WO2025076635A1 (en) * 2023-10-12 2025-04-17 Universite Laval Anti-alpha-synuclein antibodies and uses thereof
US20250282855A1 (en) 2024-03-05 2025-09-11 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0335902B1 (en) 1986-12-15 1993-12-01 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69424687T2 (de) 1993-03-09 2000-09-07 Genzyme Corp., Cambridge Verfahren zur isolierung von proteinen aus milch
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
JP2004502781A (ja) 2000-07-07 2004-01-29 パナシア　ファーマシューティカルズ　インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
SI1633189T1 (sl) 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
HUE025225T2 (en) 2007-02-23 2016-02-29 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic diseases
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
EP2154969B1 (en) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CA2758187C (en) 2009-04-09 2017-03-07 Robert Boyd Methods for preventing and/or treating degenerative disorders of the central nervous system
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
HUE041391T2 (hu) * 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
US8609820B2 (en) * 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
CN107847499A (zh) 2015-05-07 2018-03-27 阿速万科学有限责任公司 治疗神经退行性疾病的方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN109475616B (zh) 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937210A (zh) * 2016-11-15 2019-06-25 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法
CN109937210B (zh) * 2016-11-15 2023-09-15 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法

Also Published As

Publication number Publication date
MX2023009483A (es) 2023-08-22
US11524995B2 (en) 2022-12-13
PH12018500016A1 (en) 2018-07-09
DOP2018000013A (es) 2018-04-15
RS66840B1 (sr) 2025-06-30
JP7012004B2 (ja) 2022-02-10
DK3322722T3 (da) 2025-05-26
MA42439B1 (fr) 2025-05-30
PL3322722T3 (pl) 2025-06-30
ES3028882T3 (en) 2025-06-20
FI3322722T3 (fi) 2025-06-05
RU2017145653A3 (https=) 2019-11-21
EA036499B1 (ru) 2020-11-17
JO3692B1 (ar) 2020-08-27
CA2989735A1 (en) 2017-01-19
NI201800006A (es) 2018-10-18
US10364285B2 (en) 2019-07-30
US20180179270A1 (en) 2018-06-28
US20190382473A1 (en) 2019-12-19
US20180179271A1 (en) 2018-06-28
KR20180029205A (ko) 2018-03-20
HRP20250624T1 (hr) 2025-07-18
ZA201708607B (en) 2019-05-29
US10647764B2 (en) 2020-05-12
WO2017009312A1 (en) 2017-01-19
ECSP18002645A (es) 2018-03-31
JP2022174131A (ja) 2022-11-22
TW201716440A (zh) 2017-05-16
PT3322722T (pt) 2025-05-21
US20180127492A1 (en) 2018-05-10
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
NZ738315A (en) 2024-12-20
EP4582144A2 (en) 2025-07-09
GEP20207151B (en) 2020-09-25
US20210147522A1 (en) 2021-05-20
LT3322722T (lt) 2025-06-10
EP3322722A1 (en) 2018-05-23
UA125501C2 (uk) 2022-04-13
TN2018000005A1 (en) 2019-07-08
JP7138322B2 (ja) 2022-09-16
US20230312693A1 (en) 2023-10-05
TWI729992B (zh) 2021-06-11
BR112017027506A2 (pt) 2018-09-11
JP7608404B2 (ja) 2025-01-06
US10358483B2 (en) 2019-07-23
MX2018000504A (es) 2018-04-30
MA42439A (fr) 2018-05-23
SV2018005612A (es) 2018-07-20
CL2018000075A1 (es) 2018-05-11
US20210054057A1 (en) 2021-02-25
SI3322722T1 (sl) 2025-06-30
AR105336A1 (es) 2017-09-27
CR20180021A (es) 2018-03-13
AU2016292896B2 (en) 2022-02-24
US11542323B2 (en) 2023-01-03
CN115925921A (zh) 2023-04-07
IL256501A (en) 2018-02-28
CN121824750A (zh) 2026-04-10
US10647763B2 (en) 2020-05-12
US10358484B2 (en) 2019-07-23
US10358482B2 (en) 2019-07-23
HK1254358A1 (en) 2019-07-19
HUE071541T2 (hu) 2025-09-28
US20190367595A1 (en) 2019-12-05
US10800836B2 (en) 2020-10-13
US20190367594A1 (en) 2019-12-05
US11421024B2 (en) 2022-08-23
EA201792616A1 (ru) 2018-06-29
CR20230300A (es) 2023-08-25
US20170015739A1 (en) 2017-01-19
AU2016292896A1 (en) 2018-01-18
EP3322722B1 (en) 2025-03-05
KR20250051158A (ko) 2025-04-16
CN121736097A (zh) 2026-03-27
MY194944A (en) 2022-12-27
US20210061892A1 (en) 2021-03-04
RU2017145653A (ru) 2019-08-13
JP2021191763A (ja) 2021-12-16
EP4582144A3 (en) 2025-07-16
CO2017012941A2 (es) 2018-03-09
JP2025041734A (ja) 2025-03-26
KR102793383B1 (ko) 2025-04-08
CN107709361A (zh) 2018-02-16
GEAP202014670A (en) 2020-05-11
JP2018529634A (ja) 2018-10-11
US20180127491A1 (en) 2018-05-10
IL256501B (en) 2021-10-31
RU2765303C2 (ru) 2022-01-28

Similar Documents

Publication Publication Date Title
GB201512203D0 (en) Agents,uses and methods
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
IL249370A0 (en) Fap-enabled medical substances and related uses
SG11201608943VA (en) Substituted 4-phenylpiperidines, their preparaiton and use
GB201512215D0 (en) Agents,uses and methods
IL252430A0 (en) Antibodies, uses and methods
GB201603311D0 (en) New uses and methods
GB201408673D0 (en) Medicaments,uses and methods
ZA201801052B (en) Combinations and uses thereof
GB201715769D0 (en) Methods, Compositions and uses relating thereto
GB201612858D0 (en) New uses and methods
GB201715768D0 (en) Methods, compositions and uses relating thereto
GB201706349D0 (en) Methods, compositions and uses relating thereto
GB201616670D0 (en) Methods, compositions and uses relating thereto
GB2548839B (en) New uses and methods
IL254241A0 (en) Etv2 and its uses
PT3288575T (pt) Complexo de proteína-melanina bioassimilável, sua preparação e utilizações
GB201616674D0 (en) Methods, compositions and uses relating thereto
GB201616660D0 (en) Methods, compositions and uses relating thereto
GB201616666D0 (en) Methods, compositions and uses relating thereto
GB201518375D0 (en) Agents,uses and methods
GB201512211D0 (en) Agents, uses and methods
GB201512216D0 (en) Agents uses and methods
GB201616648D0 (en) Methods, compositions and uses relating thereto

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)